Literature DB >> 21431882

A putative Lynch syndrome family carrying MSH2 and MSH6 variants of uncertain significance-functional analysis reveals the pathogenic one.

Jukka Kantelinen1, Thomas V O Hansen, Minttu Kansikas, Lotte Nylandsted Krogh, Mari K Korhonen, Saara Ollila, Minna Nyström, Anne-Marie Gerdes, Reetta Kariola.   

Abstract

Inherited pathogenic mutations in the mismatch repair (MMR) genes, MSH2, MLH1, MSH6, and PMS2 predispose to Lynch syndrome (LS). However, the finding of a variant or variants of uncertain significance (VUS) in affected family members complicates the risk assessment. Here, we describe a putative LS family carrying VUS in both MSH2 (c.2768T>A, p.Val923Glu) and MSH6 (c.3563G>A, p.Ser1188Asn). Two colorectal cancer (CRC) patients were studied for mutations and identified as carriers of both variants. In spite of a relatively high mean age of cancer onset (59.5 years) in the family, many CRC patients and the tumor pathological data suggested that the missense variation in MSH2, the more common susceptibility gene in LS, would be the predisposing alteration. However, MSH2 VUS was surprisingly found to be MMR proficient in an in vitro MMR assay and a tolerant alteration in silico. By supplying evidence that instead of MSH2 p.Val923Glu the MSH6 p.Ser1188Asn variant is completely MMR-deficient, the present study confirms the previous findings, and suggests that MSH6 (c.3563G>A, p.Ser1188Asn) is the pathogenic mutation in the family. Moreover, our results strongly support the strategy to functionally assess all identified VUS before predictive gene testing and genetic counseling are offered to a family.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21431882     DOI: 10.1007/s10689-011-9436-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  21 in total

1.  Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein.

Authors:  Saara Ollila; Laura Sarantaus; Reetta Kariola; Philip Chan; Heather Hampel; Elke Holinski-Feder; Finlay Macrae; Maija Kohonen-Corish; Anne-Marie Gerdes; Päivi Peltomäki; Elisabeth Mangold; Albert de la Chapelle; Marc Greenblatt; Minna Nyström
Journal:  Gastroenterology       Date:  2006-08-22       Impact factor: 22.682

2.  Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair.

Authors:  Elda Cannavo; Giancarlo Marra; Jacob Sabates-Bellver; Mirco Menigatti; Steven M Lipkin; Franziska Fischer; Petr Cejka; Josef Jiricny
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  Analysis of EPCAM protein expression in diagnostics of Lynch syndrome.

Authors:  Matthias Kloor; Anita Y Voigt; Hans K Schackert; Peter Schirmacher; Magnus von Knebel Doeberitz; Hendrik Bläker
Journal:  J Clin Oncol       Date:  2010-11-29       Impact factor: 44.544

4.  Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations.

Authors:  Y Wu; M J Berends; R G Mensink; C Kempinga; R H Sijmons; A G van Der Zee; H Hollema; J H Kleibeuker; C H Buys; R M Hofstra
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

5.  Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree.

Authors:  A Wagner; Y Hendriks; E J Meijers-Heijboer; W J de Leeuw; H Morreau; R Hofstra; C Tops; E Bik; A H Bröcker-Vriends; C van Der Meer; D Lindhout; H F Vasen; M H Breuning; C J Cornelisse; C van Krimpen; M F Niermeijer; A H Zwinderman; J Wijnen; R Fodde
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

6.  Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant.

Authors:  Maran J W Berends; Ying Wu; Rolf H Sijmons; Rob G J Mensink; Tineke van der Sluis; Jannet M Hordijk-Hos; Elisabeth G E de Vries; Harry Hollema; Arend Karrenbeld; Charles H C M Buys; Ate G J van der Zee; Robert M W Hofstra; Jan H Kleibeuker
Journal:  Am J Hum Genet       Date:  2002-01       Impact factor: 11.025

7.  MutSbeta exceeds MutSalpha in dinucleotide loop repair.

Authors:  J Kantelinen; M Kansikas; M K Korhonen; S Ollila; K Heinimann; R Kariola; M Nyström
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

8.  Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.

Authors:  Yvonne M C Hendriks; Anja Wagner; Hans Morreau; Fred Menko; Astrid Stormorken; Franz Quehenberger; Lodewijk Sandkuijl; Pal Møller; Maurizio Genuardi; Hans Van Houwelingen; Carli Tops; Marjo Van Puijenbroek; Paul Verkuijlen; Gemma Kenter; Anneke Van Mil; Hanne Meijers-Heijboer; Gita B Tan; Martijn H Breuning; Riccardo Fodde; Juul Th Wijnen; Annette H J T Bröcker-Vriends; Hans Vasen
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

9.  Structure of the human MutSalpha DNA lesion recognition complex.

Authors:  Joshua J Warren; Timothy J Pohlhaus; Anita Changela; Ravi R Iyer; Paul L Modrich; Lorena S Beese
Journal:  Mol Cell       Date:  2007-05-25       Impact factor: 17.970

10.  A new variant database for mismatch repair genes associated with Lynch syndrome.

Authors:  Michael O Woods; Phillip Williams; Amanda Careen; Laura Edwards; Sylvia Bartlett; John R McLaughlin; H Banfield Younghusband
Journal:  Hum Mutat       Date:  2007-07       Impact factor: 4.878

View more
  1 in total

1.  CoDP: predicting the impact of unclassified genetic variants in MSH6 by the combination of different properties of the protein.

Authors:  Hiroko Terui; Kiwamu Akagi; Hiroshi Kawame; Kei Yura
Journal:  J Biomed Sci       Date:  2013-04-28       Impact factor: 8.410

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.